Expert Opinion on Therapeutic Patents

Papers
(The H4-Index of Expert Opinion on Therapeutic Patents is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Multicomponent reactions (MCR) in medicinal chemistry: a patent review (2010-2020)114
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-1981
Patented therapeutic drug delivery strategies for targeting pulmonary diseases62
An updated patent review of p38 MAP kinase inhibitors (2014-2019)51
Antibacterial carbonic anhydrase inhibitors: an update on the recent literature50
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review46
Repurposing drugs for the management of COVID-1944
Antimicrobial peptides (AMPs): a patent review (2015–2020)43
Sirtuin modulators: where are we now? A review of patents from 2015 to 201937
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)37
Xanthine oxidase inhibitors: patent landscape and clinical development (2015–2020)34
Biofilm and Quorum Sensing inhibitors: the road so far34
N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)33
Antibiotic resistance and bacterial biofilm32
Microneedles as an alternative technology for transdermal drug delivery systems: a patent review31
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present31
Natural compounds and extracts as novel antimicrobial agents31
Inhibitory activities of indolizine derivatives: a patent review30
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents30
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)29
The therapeutic potential of PROTACs29
A deadly spillover: SARS-CoV-2 outbreak28
An updated patent review of anticancer Hsp90 inhibitors (2013-present)27
An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)27
An updated patent review of VEGFR-2 inhibitors (2017-present)27
Synthetic molecules as DprE1 inhibitors: A patent review27
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)26
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)26
0.015991926193237